Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer

被引:16
|
作者
Daniels, Molly S. [1 ]
Urbauer, Diana L. [2 ]
Stanley, Jennifer L. [1 ]
Johnson, Kristin G. [3 ]
Lu, Karen H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77230 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Quantitat Sci, Houston, TX 77230 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Nursing, Houston, TX 77230 USA
关键词
BRCA1; BRCA2; genetic testing; ovarian cancer; cancer recurrence; NONPOLYPOSIS COLORECTAL-CANCER; BRCA2; MUTATIONS; DNA-REPAIR; SURVIVAL; SUSCEPTIBILITY; PREVALENCE; POLYMERASE; INHIBITORS; CARCINOMA; FEATURES;
D O I
10.1097/GIM.0b013e3181ab2295
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: To determine when, in reference to the course of their treatment. women with ovarian cancer are seen for genetic Counseling. as well as to determine what factors influence this timing. Methods: Single institution retrospective chart review of patients with ovarian cancer Who Underwent BRCA1/BRCA2 genetic testing. Results: Thirty-three percent of our sample (n = 100) were seen for genetic counseling after ovarian cancer recurrence. In four cases, genetic test results were disclosed to next of kin. Thirty percent of women seen for genetic counseling after recurrence received their initial treatment elsewhere. Women with a history of breast cancer were significantly more likely to be seen for genetic counseling at an earlier phase of their treatment than women with no history of breast cancer. Conclusion: We found that one third of patients with ovarian cancer who underwent genetic testing were seen for initial genetic counseling after disease recurrence. In some cases, genetic counseling took place during the end of life care. with genetic test results disclosed to next of kin. Given the poor prognosis of women with recurrent ovarian cancer, we advocate providing genetic Counseling at the time of initial ovarian cancer treatment both in comprehensive cancer centers and in community oncology settings. Genet Med 2009:11(9):624-628.
引用
收藏
页码:624 / 628
页数:5
相关论文
共 50 条
  • [21] Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations: Missed Opportunities
    Herman, Jonathan
    OBSTETRICS AND GYNECOLOGY, 2010, 116 (02): : 440 - 441
  • [22] Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations Missed Opportunities
    Meyer, Larissa A.
    Anderson, Meaghan E.
    Lacour, Robin A.
    Suri, Anuj
    Daniels, Molly S.
    Urbauer, Diana L.
    Nogueras-Gonzalez, Graciela M.
    Schmeler, Kathleen M.
    Gershenson, David M.
    Lu, Karen H.
    OBSTETRICS AND GYNECOLOGY, 2010, 115 (05): : 945 - 952
  • [23] Cost Effectiveness Analysis of Genetic Testing for Breast and Ovarian Cancer Susceptibility Genes: BRCA1 and BRCA2
    Kaldate, Rajesh
    Huston, Alissa
    McCoy, Heidi
    Cardeiro, Dawn
    Noyes, Katia
    BREAST JOURNAL, 2014, 20 (03): : 325 - 326
  • [24] Evolution and organization of genetic testing services for breast and ovarian cancer predisposition (BRCA1, BRCA2) in France
    Julian-Reynier, C
    Sévilla, C
    Bourret, P
    Sobol, H
    Nogues, C
    EUROCANCER 2002, 2002, : 205 - 206
  • [25] Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations
    Tavella, K.
    Villanucci, A.
    Vannini, L.
    Rossi, V.
    Fantechi, B.
    Capone, G.
    Putignano, A. L.
    Gensini, F.
    Porfirio, B.
    Amunni, G.
    Mazzei, T.
    Mini, E.
    Papi, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
    Eccleston, Anthony
    Bentley, Anthony
    Dyer, Matthew
    Strydom, Ann
    Vereecken, Wim
    George, Angela
    Rahman, Nazneen
    VALUE IN HEALTH, 2017, 20 (04) : 567 - 576
  • [27] Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2
    Bluman, LG
    Rimer, BK
    Berry, DA
    Borstelmann, N
    Iglehart, JD
    Regan, K
    Schildkraut, J
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 1040 - 1046
  • [28] A review of BRCA1 & BRCA2 testing
    Lillis, S
    Mattocks, C
    Tarpey, P
    Daboo, L
    Whittaker, J
    JOURNAL OF MEDICAL GENETICS, 2003, 40 : S72 - S72
  • [29] Genetic testing for breast cancer susceptibility:: Frequency of BRCA1 and BRCA2 mutations
    Ganguly, A
    Leahy, K
    Marshall, AM
    Dhulipala, R
    Godmilow, L
    Ganguly, T
    GENETIC TESTING, 1997, 1 (02): : 85 - 90
  • [30] Breast and ovarian cancer screening in women undergoing genetic counseling and genetics testing for BRCA1 and BRCA2 gene mutations.
    Kelly, KM
    Ellington, LA
    Leventhal, H
    Porter, K
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2762S - 2762S